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INTRODUCTION
Neutropenia is frequently observed in neonates. It has been
reported that neutropenia occurs in as many as 8% of all pa-
tients admitted to neonatal intensive care units (NICUs) (1,
2). In many such cases, neutropenia is usually transient and
conveys no survival disadvantage. However, in other cases it
is prolonged and severe, and neonates are at high risk of devel-
oping infections (2). Neonatal alloimmune neutropenia (NAN)
is a disease that causes severe and prolonged neutropenia in
neonates. NAN occurs when a mother becomes sensitized to
a foreign antigen of paternal origin that is present on fetal
granulocytes (1-4). These fetal granulocyte antigens sensitize
the mother and provoke antibody production. Moreover, ma-
ternal immunoglobulin G (IgG) antibody readily crosses the
placenta and destroys fetal granulocytes (3). Neutropenia is
typically self-limiting and lasts for several weeks. A wide vari-
ety of antigenic targets have been identified in NAN (3-10),
but target antigens remain unidentified in about a half of cases
(8-11). To confirm NAN, granulocyte antibody test and gran-
ulocyte antigen typing should be performed on both neona-
tal and maternal blood. However, granulocyte antibody test
is technically complicated and difficult to maintain (11, 12).
Therefore, in Korea, no report has been issued on the incidence
of granulocyte antibody in neonates with neutropenia, the
target antigens of this antibody, and the estimated incidence
of NAN. 
In this study, we detected granulocyte antibodies in a group
of neonates with neutropenia, identified the antibody speci-
ficities, and confirmed a few cases of NAN. We also estimat-
ed the incidence of NAN in Korea. 
MATERIALS AND METHODS
Samples and study group 
All neonates admitted to the Neonatal Intensive Care Unit
of Sanggye Paik Hospital from April 2000 to March 2005
were analyzed (n=856). Complete blood counts and differ-
ential cell counts were evaluated. If neonates showed at least
one neutropenic WBC during the first 28 days and providing
their parents had given formal consent, they were enrolled in
this study (n=105). Neutropenia was defined using the refer-
ence range established by Manroe et al. (13) and Mouzinho et
al. (14). The median age of these neonates at first neutropenia
was 11 days (range from 0 to 28 days [mean±SD, 11±5.1
days]). Their male to female ratio was 1.05 to 1 (54 male, 51
female). 112 sera and 105 EDTA sample were collected from
the 105 nenoates. In addition, six pairs of serum and EDTA
samples were collected from mothers whose babies’ sera show-
ed positive reactions by granulocyte antibody testing. Serum
samples were stored immediately at -70℃until required. To
detect granulocyte antibody in neonate sera, we used the mixed
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Granulocyte Antibodies in Korean Neonates with Neutropenia 
Neonatal alloimmune neutropenia (NAN) is a disease that can cause severe and
prolonged neutropenia in neonates. However, no report is available on the incidence
of granulocyte antibody in neonates, the target antigen of this antibody, and the esti-
mated incidence of NAN in Korea. Among a total of 856 neonates admitted to a neo-
natal intensive care unit (NICU) over a five year period, a total of 105 neonates with
neutropenia were enrolled in this study. Positive reactions were observed in the sera
of six neonates (5.7%, 6/105) by mixed passive hemagglutination assay (MPHA).
To confirm the presence of NAN, MPHA and granulocyte antigen typing (HNA-1a,
-1b, -2a, -4a, and -5a) were performed on neonatal and maternal blood. To differ-
entiate granulocyte antibody and HLA antibody, MPHA was also performed using
HLA antibody adsorbed serum. We confirmed three cases (2.9%, 3/105) of NAN
among neonates with neutropenia in which granulocyte antibody specificities (two
anti-HNA-1b and one anti-HNA-1a) and fetomaternal granulocyte antigen mismatch-
es were identified. In this study, the estimated incidence of NAN was 0.35% (3/856)
among neonates admitted to NICUs in Korea. 
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passive hemagglutination assay (MPHA) (12), using extracted
granulocyte antigens coated onto microplates. These were
obtained from six voluntary donors whose granulocyte anti-
gen types had been identified. When an antibody was detect-
ed, MPHA was re-performed with HLA antibody adsorbed
serum (12, 15) to differentiate granulocyte antibody and HLA
antibody. MPHA was then performed using the mother’s
serum and granulocyte antigen typing (HNA-1a, HNA-1b,
HNA-4a, and HNA-5a genotyping and HNA-2a serotyp-
ing) was performed on both neonatal and maternal blood to
support alloimmunization due to fetomaternal granulocyte
antigen mismatches. 
Extracted granulocyte antigen-coated microplates
Granulocytes were isolated and an extracted granulocyte
antigen-coated microplate was prepared as a solid phase, ac-
cording to the protocol described by Araki et al. (12). Gran-
ulocytes were isolated from EDTA blood by utilizing a den-
sity gradient medium (PMN isolation medium, Robbins Sci-
entific, Sunnyvale, CA, U.S.A.). Isolated granulocytes were
suspended in normal saline containing 3% sucrose at a cell
density of 3,000/ L and then allowed to stand for three days
at 4℃. 25  L of each supernatant was placed in a well of a
U-bottomed microplate (Maxisorp Lockwellmodule, Nunc,
Roskide, Denmark) and allowed to stand overnight to allow
the granulocyte antigen-coating to form. Microplates were
stored at -70℃before required for MPHA testing. 
Granulocyte donors
Six donors were selected from 32 voluntary donors to pre-
pare extracted granulocyte antigen-coated microplates. The
six donors’ granulocyte antigen types were as follows: 
donor 1, HNA-1a+, HNA-1b+, HNA-2a+, HNA-4a+,
HNA-5a+; donor 2, HNA-1a+, HNA-1b+, HNA-2a-, HNA-
4a+, HNA-5a+; donor 3, HNA-1a+, HNA-1b-, HNA-
2a+, HNA-4a+, HNA-5a+; donor 4, HNA-1a-, HNA-1b+,
HNA-2a+, HNA-4a+, HNA-5a+; donor 5, HNA-1a+, HNA-
1b-, HNA-2a+, HNA-4a+, HNA-5a+; donor 6, HNA-1a-,
HNA-1b+, HNA-2a-, HNA-4a+, HNA-5a+. More than
two HNA-1a, HNA-1b, and HNA-2a-positive donors were
included, and more than two HNA-1a HNA-1a, HNA-1b,
and HNA-2a-negative donors. All of donors were HNA-4a-
positive and HNA-5a-positive, but none were HNA-4a-
negative and HNA-5a-negative. 
Granulocyte antibody test using MPHA 
To detect granulocyte antibody, sera from neonates and mo-
thers were tested by MPHA. The extracted granulocyte anti-
gens from the six donors coated onto the U-bottomed mi-
croplates, were used as a solid phase. The negative control
serum was derived from a healthy male donor with no his-
tory of transfusion. Antisera (anti-HNA1a, anti-HNA-1b,
anti-HNA-2b, and anti-HLA antibody) were used as positive
controls and sheep RBCs coated with rabbit F(ab′ )2 anti-hu-
man IgG were used as indicator cells. Tests were performed
according to the protocols described by Araki et al. (14). To
remove HLA antibody from serum, 0.2 mL of serum was in-
cubated with 5×10
9 pooled platelets at 37℃ for 30 min.
Adsorbed serum was recovered after centrifugation at 10,000
gfor 5 min (15). 
HNA-1a, HNA-1b, and HNA-4a genotyping by PCR 
DNA was isolated from the EDTA blood samples of neo-
nates and their mothers using QIAamp DNA Blood Mini
kits (Qiagen GmbH, Hilden, Germany). To type HNA-1a,
HNA-1b, and HNA-4a, polymerase chain reactions with
sequence-specific primers (PCR-SSP) were performed, accord-
ing to the protocols described by Bux et al. (16) and Clague
et al. (17). NA1 (5′ -CAGTGGTTTCACAATGAA-3′ ) was
used as a sense primer specific for HNA-1a allele (FCGR3B*
1) and NA2 (5′ -CAATGGTACAGCGTGCTT-3′ ) for HNA-
1b allele (FCGR3B*2). NA reverse (5′ -ATGGACTTCTAG
CTGCAC-3′ ) was used as an antisense primer common to
HNA-1a and HNA-1b alleles. Pos-R (5′ -AGTGACTCAC-
CCTGCATGC-3′ ) was used as an antisense primer specific
for HNA-4a-positive allele and Neg-R (5′ -AGTGACTCA
CCCTGCATGT-3′ for HNA-4a-negative allele. HNA-4a-
F (5′ -CTCCCCACAGGGTGGTG-3′ ) was used as a sense
primer common to HNA-4a-positive and HNA-4a-negative
allele. For internal control purposes, two primers (HGH I
and HGH II) amplifying a 439 bp fragment of the human
growth hormone gene (HGH) were used. Amplification was
performed in a 20  L reaction mixture containing the follow-
ing: 0.2  M of each primer; 200  M dATP, dCTP, dTTP,
and dGTP; 10 mM Tris-HCl (pH 9.0), 1.5 mM MgCl2, 40
mM KCl; 1 unit of Taq polymerase (Bioneer, Daejeon, Korea);
and 1  L of DNA sample. Amplification was preformed in
a DNA thermal cycler (iCycler Thermal Cycler, Bio-Rad La-
boratories, Hercules, CA, U.S.A.). Each cycle consisted of the
following: predenaturation at 95℃ for 3 min and 30 ampli-
fication cycles of (denaturation at 95℃ for 1 min, primer an-
nealing at 58℃for 1 min, and extension at 72℃for 1 min).
The sizes of the amplified DNA fragments were 141 bp, 219
bp, and 124 bp for the HNA-1a, HNA-1b, and HNA-4a
genes, respectively (Fig. 1). 
HNA-5a genotyping by reverse transcription (RT) and
PCR allele-specific restriction enzyme analysis (PCR-
ASRA)
To type HNA-5a, RT and PCR-ASRA were performed ac-
cording to the protocol described by Simsek et al. (18). RNA
was isolated from the EDTA blood samples of neonates and
their mothers using QIAamp RNA Blood Mini kits (QiagenGranulocyte Antibodies in Neonates with Neutropenia 629
GmbH, Hilden, Germany). Reverse transcription of 0.5  g
of total RNA was performed in a final volume of 20  L con-
taining 5  M random hexamer, 1 mM of each dNTP, 2 units
of RNase inhibitor, and 9 units of reverse transcriptase (Bio-
neer, Daejeon, Korea). After incubation at 42℃ for 60 min,
samples were heated for 5 min at 94℃to terminate reactions.
The primers L5 (5′ -ATTTCTCTCTTTGGGAGGAGG-3′ )
and L5A (5′ -TGGGTATG TTGTGGTCGTGG-3′ ) were
used to amplify the coding region of the cDNA. The PCR
product (709 bp) was treated with restriction endonuclease
Bsp1286I (Takara Biotechnology, Otsu, Japan), size-separated
on a 2% agarose gel with ethidium bromide, and visualized
with UV light. In HNA-5a-positive homozygote samples,
three fragments of 297 bp, 217 bp, and 195 bp were gener-
ated; in HNA-5a-negative homozygote samples, two frag-
ments of 412 bp and 297 bp were generated; and in HNA-
5a heterozygote samples, four fragments of 412 bp, 297 bp,
217 bp, and 195 bp were generated (Fig. 2).
HNA-2a serotyping using MPHA
To type HNA-2a antigen on neonates’ and their mothers’
granulocytes, MPHA was performed using the protocol de-
scribed above. Anti-HNA-2b was used as a typing antiserum
and U-bottomed microplates coated with extracted granulo-
cyte antigens from mothers and neonates were used as solid
phases. 
RESULTS 
Positive reactions were observed in 13 sera from 6 neonates
(5.7%, 6/105) among 105 neonates with neutropenia using
Fig. 2. HNA-5a genotyping by Bsp1,286 I allele-specific restriction
enzyme analysis (ASRA). Lane 1 shows a DNA ladder marker (Bi-
oneer, Daejeon, Korea); lane 2 shows an undigested 709 bp PCR
product of the  L chain of  2 integrin cDNA; lane 3 shows an HNA-
5a+ homozygote sample (297 bp, 217 bp, and 195 bp); lane 4
shows a HNA-5a heterozygote samples (412 bp, 297 bp, 217 bp,
and 195 bp); and lane 5 shows a HNA-5a- homozygote sample
(412 bp, and 297 bp).
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Fig. 1. HNA-1a, HNA-1b, HNA-4a genotyping by PCR-SSP. Lane
9 shows a DNA ladder marker (Bioneer, Daejeon, Korea). The am-
plification products (439 bp) of the internal control (HGH gene) are
present in each lane. Lanes 1, 3, 5, and 7 are positive controls for
HNA-1a (141 bp), HNA-1b (219 bp), HNA-4a-positive (124 bp), and
HNA-4a-negative (124 bp), respectively. Lanes 2, 4, 6, and 8 are
negative controls for HNA-1a, HNA-1b, HNA-4a+, and HNA-4a-,
respectively. Lanes 10-13 contain amplification products of HNA-
1a, HNA-1b, HNA-4a+, and HNA-4a-, respectively from a DNA sa-
mple that is a HNA-1-heterozygote (HNA-1a/HNA-1b) and a HNA-
4a-heterozygote (HNA-4a+/HNA-4a-).
124 bp
141 bp
219 bp
Neonate 1 + + + - + - + + + - + - HNA-1a 
Mother 1 + + + - + - + + + - + -
Neonate 2 + + - + - + + + - + - + HNA-1b
Mother 2 + + - + - + + + - + - +
Neonate 3 + + + + + + + + - + - + HNA-1b, HLA
Mother 3 + + + + + + + + - + - +
Neonate 4 + - + + + - + - - - ± - Unid granulocyte, HLA
Mother 4 + - + + + - + - - - + -
Neonate 5 + ± - -- + ------ H L A
Mother 5 + + - - - + - - - - - -
Neonate 6 + ± - -- + ------ H L A
Mother 6 + + - - - + - - - - - -
Table 1. Characteristics of antibodies in sera from neonates with neutropenia and their mothers
Case No.
D1 D2 D3 D4 D5 D6 D1 D2 D3 D4 D5 D6
Untreated sera HLA antibody adsorbed sera
Antibody target
D1-D6, donor 1-donor 6; Unid granulocyte, unidentified granulocyte antigen; +, positive; ±, weakly positive; -, negative.MPHA. The positive reactions were as follows: one case of
anti-HNA-1a (case 1), one case of anti-HNA-1b (case 2), one
case of anti-HNA-1b with HLA antibody (case 3), one case
of granulocyte antibody with unknown specificity and HLA
antibody (case 4), and two cases of HLA antibody (cases 5, 6)
(Table 1). We confirmed three cases (2.9%, 3/105) of NAN
(case 1-3), in which granulocyte antibody specificities were
identified and fetomaternal granulocyte antigen mismatches
were confirmed (Table 1, 2, Fig. 3). In other cases with posi-
tive reactions (cases 4-6), maternal sera showed the same re-
action patterns as neonatal sera, but there was no fetomater-
nal granulocyte antigen mismatch (Table 1). 
The three cases of NAN are summarized in Table 2. All
were born by spontaneous vaginal delivery. They were admit-
ted to the NICU because of; prematurity (case 1), neonatal
jaundice (case 2), and transient tachypnea of the newborn
(case 3). All received prophylactic antibiotics (gentamicin
and ampicillin/sublactam) for potential sepsis, although blood,
urine, and gastric aspirate cultures proved sterile later. All
received subcutaneous injections of recombinant human gran-
ulocyte colony-stimulating factor (rhG-CSF) at 10  g/kg/day
for three days. Their absolute neutrophil counts increased
after treatment and were maintained at more than 1,500/ L
until discharge. Maternal investigations were performed and
detailed clinical histories were taken to exclude factors relat-
ed to maternal disease as a cause of neonatal neutropenia. With
the exception of case 3 (pre-eclampsia), maternal diseases were
not implicated. Findings of maternal complete blood counts
were also normal. All were discharged with clinical improve-
ment. 
The estimated incidence of neutropenia in neonates admit-
ted to a NICU was about 12.3% (105/856). We also estimat-
ed that the incidence of NAN was 0.35% (3/856) among neo-
nates admitted to a NICU.
DISCUSSION
In present study, the estimated incidence of neutropenia
in neonates admitted to a NICU was about 12.3% (105/806),
which is higher than the incidence (7%) reported in U.S.A.
(2). Estimates of the incidence of NAN can vary widely and
range from 0.1 to 20% (1, 6-8), but such estimates are not
easily compared because of differences in study designs, peri-
ods, and the test methods used. In the present study, the study
population was neonates in a NICU and the estimated inci-
dence of NAN was 0.35% (3/856). 
For the NAN development, there should be a fetomater-
nal granulocyte mismatch and the pregnant woman should
be alloimmunized against the granulocyte antigens. Zupan-
ska et al. (5) reported fetomaternal granulocyte antigen mis-
matches (HNA-1a and -1b only) in 19.6% of mothers, and
granulocyte-specific antibodies in 3% of fetomaternal incom-
patible mothers (alloimmunization in 0.6% of mothers). The
authors suggested that NAN related to two antigens (HNA-1a
and -1b) occurs in less than 0.1% and severe NAN in 0.06%
(5). If HNA-1a and HNA-1b only were involved [HNA-1a
and -1b gene frequencies were reported to be 0.52 and 0.48
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Fig. 3. Granulocyte antibody test using the mixed passive hemag-
glutination assay (MPHA). The neonates’ and mothers’ sera were
tested using extracted granulocyte antigen-coated microplates
(from six donors) as a solid phase and sheep RBCs coated with
rabbit F(ab′ )2 anti-human IgG as indicator cells. To differentiate
granulocyte antibody from HLA antibody, sera (left half) with pos-
itive reactions were compared with HLA antibody adsorbed sera
(right half). In the sera of neonate 1 (N1) and her mother (M1), anti-
HNA-1a; in the sera of neonate 2 (N2) and his mother (M2), anti-
HNA-1b; in the sera of neonate 3 (N3) and his mother (M3), anti-
HNA-1b and anti-HLA. 
P, pasitive control; N, negative control.
Untreated sera HLA antibody adsorbed sera
D1
P
N
N1
M1
N2
M2
N3
M3
D2 D3 D4 D5 D6 D1 D2 D3 D4 D5 D6
Sex Female Male Male
Body weight (g) 2,810 2,980 3,150
Gestational age  36 40 39
(weeks)
Clinical features Premature Neonatal  TTN; pre-
infant jaundice eclapmsia
Initial WBC ( / L) 7,200 (day 1) 8,100 (day 8) 5,850 (day 1)
Initial ANC ( / L) 430 730 650
Initial platelets ( / L) 191,000 243,000 120,000
Duration of neutropenia  7 days 10 days 13 days
rhG-CSF  Day 6, 7, 8 Day 10, 11, 12 Day 12, 13,14,
Diagnosis of NAN Day 5 Day 10 Day 11
Antigen type HNA-1a,-1b,  HNA-1a,-1b,  HNA-1a,-1b, 
-2a,-4a,-5a -2a,-4a,-5a -2a,-4a,-5a
Mother’s antigen type HNA-1b,-2a, HNA-1a,-2a, HNA-1a,-2a,
-4a,-5a -4a,-5a -4a,-5a
Antibody Anti-HNA-1a Anti-HNA-1b Anti-HNA-1b, 
anti-HLA
Table 2. Clinical characteristics of three cases of neonatal allo-
immune neutropenia 
Case 1 Case 2 Case 3
Days are based on postnatal age. 
ANC, absolute neutrophil count; rhG-CSF, recombinant human granu-
locyte colony-stimulating factor; HNA, human neutrophil antigen; TTN,
transient tachypnea of the newborn.in Koreans, respectively (20)], fetomaternal granulocyte anti-
gen mismatches would be present in 18% and alloimmuniza-
tion in 0.5% of mothers in Korea. However, a much higher
incidence of antigen mismatches, alloimmunization, and NAN
would be expected based on considerations of all possible feto-
maternal granulocyte antigen mismatches. In fact the inci-
dence of overall alloimmunization in pregnant women varies
widely ranging from 1.1% to 20% (5, 7, 8). Our unpublished
data suggest that the incidence of alloimmunization against
granulocyte antigens is 3.5% (6/170) in mothers [HNA-1a
and -1b, 2.4% (4/170)] in Korea.
A wide variety of antigens including the human neutrophil
antigen (HNA) system and HLA have been identified in
NAN (1, 3-10), and nearly a half of all cases are mediated by
antibodies that bind to HNA-1a, -1b, or -2a (8-10). In the
present study, anti-HNA-1b was present in two cases, anti-
HNA-1a in one case, and a granulocyte antibody with un-
known specificity was present in another. HLA antibodies
were present in four cases (two with HLA antibodies only,
one with anti-HNA-1b, and one with unidentified granulo-
cyte antibody). HLA antibodies are frequently detected in
NAN, but it is generally held that they do not give rise to
NAN, because the antibodies are adsorbed by the placenta
and by soluble antigens in the fetal circulation (10). How-
ever, it has been controversially claimed that HLA antibody
can cause NAN in a few cases (8, 10). In this study no evi-
dence indicated that HLA antibody is the etiology of neu-
tropenia. In Caucasians HNA-1a is the most common anti-
gen involved in NAN, HNA-1b the second, and HNA-2a
the third (8-10). In view of the reported gene frequencies of
the HNA system (19), fetomaternal mismatches due to HNA-
1b are more common in Asians than in Caucasian, and it is
expected that anti-HNA-1b antibody may be more common
in Asians than in Caucasians. In the present study, two anti-
HNA-1b antibodies and an anti-HNA-1a antibody were
identified, which supported the expectation that anti-HNA-
1b antibody might be more common than anti-HNA-1a anti-
body in Korean.
In summary we confirmed three cases of NAN, identified
granulocyte antibody, and estimated the incidence of NAN in
Korea. We conclude that NAN is not a common disease among
neonates, but that it should also be considered as a possible
cause of unexplained neutropenia among neonates in Korea. 
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